Neumora Therapeutics (NMRA) News Today $10.63 -0.49 (-4.41%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)December 25 at 1:05 AM | americanbankingnews.comNeumora: Koastal-1 Readout For MDD Treatment Is First Study On DeckDecember 24 at 2:04 PM | seekingalpha.comNeumora Therapeutics (NASDAQ:NMRA) Shares Down 3% - Should You Sell?Neumora Therapeutics (NASDAQ:NMRA) Stock Price Down 3% - Should You Sell?December 24 at 12:11 PM | marketbeat.comNeumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA)Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors purchased 3,760 put options on the company. This represents an increase of approximately 47% compared to the average daily volume of 2,556 put options.December 23 at 10:29 AM | marketbeat.comState Street Corp Has $23.66 Million Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)State Street Corp increased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 65.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,790,707 shares of the company's stock after aDecember 23 at 3:26 AM | marketbeat.comWhat is HC Wainwright's Estimate for NMRA Q1 Earnings?December 20, 2024 | americanbankingnews.comAnalysts Set Expectations for NMRA Q1 EarningsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Neumora Therapeutics in a research report issued on Monday, December 16th. HC Wainwright analyst D. Tsao anticipates that the company will post earningsDecember 18, 2024 | marketbeat.comPositive Outlook for Neumora Therapeutics Amid Key Milestones and Competitive EdgeDecember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)December 17, 2024 | americanbankingnews.comNeumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research note on Monday.December 16, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $1.10 Million Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Point72 Asset Management L.P. acquired a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 83,077 shares of the company's stoDecember 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Charles Schwab Investment Management Inc. raised its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 139.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownDecember 10, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five haveDecember 8, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)December 6, 2024 | markets.businessinsider.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LPWexford Capital LP raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 90.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 217,879 shares of the company's stock after buying an additional 103,285 sharesDecember 6, 2024 | marketbeat.comFmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Fmr LLC lessened its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 10.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,749,156 shares of the company's stock after selliDecember 5, 2024 | marketbeat.comCerity Partners LLC Acquires Shares of 242,900 Neumora Therapeutics, Inc. (NASDAQ:NMRA)Cerity Partners LLC bought a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 242,900 shares of the company's stock, valued at approximately $3,209,000. Cerity Partners LLCDecember 1, 2024 | marketbeat.comNeumora Therapeutics' (NMRA) "Outperform" Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research note on Friday.November 22, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | insidermonkey.comNeumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | msn.comHC Wainwright Issues Pessimistic Outlook for NMRA EarningsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings estimates for Neumora Therapeutics in a research note issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings pNovember 15, 2024 | marketbeat.comFY2024 EPS Estimate for Neumora Therapeutics Cut by AnalystNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Investment analysts at William Blair reduced their FY2024 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company wNovember 15, 2024 | marketbeat.comThis biotech’s stock could double if its treatment for major depressive disorder succeeds, says MizuhoNovember 14, 2024 | marketwatch.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comNeumora Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comNeumora Therapeutics (NASDAQ:NMRA) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPSNeumora Therapeutics (NASDAQ:NMRA - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same period last year, the business posted ($1.14) EPS.November 13, 2024 | marketbeat.comNeumora Therapeutics' (NMRA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday.November 13, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by AnalystsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating onNovember 13, 2024 | marketbeat.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | finanznachrichten.deNeumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comMizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA)November 12, 2024 | markets.businessinsider.comNeumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comJP Morgan Downgrades Neumora Therapeutics (NMRA)November 6, 2024 | msn.comCautious Hold on Neumora Therapeutics Amid Uncertainty in KOASTAL-1 Trial OutcomesNovember 6, 2024 | markets.businessinsider.comNeumora Therapeutics to Participate in Upcoming Conferences in NovemberNovember 6, 2024 | globenewswire.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down - Here's What HappenedNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down - Should You Sell?November 5, 2024 | marketbeat.comNeumora Therapeutics (NMRA) to Release Earnings on TuesdayNeumora Therapeutics (NASDAQ:NMRA) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641761)November 5, 2024 | marketbeat.comAuour Investments LLC Purchases New Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Auour Investments LLC acquired a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 250,000 shares of the coNovember 5, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Downgraded to "Neutral" Rating by JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $18.00 to $15.00 in a research report on Tuesday.November 5, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5% - Time to Sell?Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5% - Here's WhyOctober 25, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sees Large Volume Increase - Still a Buy?Neumora Therapeutics (NASDAQ:NMRA) Sees Unusually-High Trading Volume - What's Next?October 23, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider SellingNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider SellingOctober 21, 2024 | marketbeat.comSG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)SG Americas Securities LLC decreased its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 62.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,581 shares of the company's stock after selling 36,026 shares during tOctober 21, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Director Matthew K. Fust Sells 14,049 SharesOctober 19, 2024 | insidertrades.comNeumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sees Unusually-High Trading Volume - Should You Buy?Neumora Therapeutics (NASDAQ:NMRA) Sees Strong Trading Volume - Still a Buy?October 16, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company grew its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 79.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 111,8October 13, 2024 | marketbeat.comInsider Selling: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells 5,563 Shares of StockOctober 12, 2024 | insidertrades.comStifel Nicolaus Remains a Buy on Neumora Therapeutics, Inc. (NMRA)October 12, 2024 | markets.businessinsider.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 SharesNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Robert A. Lenz sold 5,563 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares in the company, valued at $4,847,719.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.October 11, 2024 | marketbeat.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼0.690.56▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼93▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Halozyme Therapeutics News Today Krystal Biotech News Today Scholar Rock News Today ADMA Biologics News Today Arcellx News Today Immunovant News Today Alvotech News Today CRISPR Therapeutics News Today Denali Therapeutics News Today Twist Bioscience News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
